Seminars in Oncology
Volume 36, Issue 4 , Pages 338-346, August 2009

Small Round Cell SarcomasDisclosures

  • Stephen L. Lessnick

      Affiliations

    • Huntsman Cancer Institute, Salt Lake City, UT
    • These authors contributed equally to this work.
  • ,
  • A. Paolo Dei Tos

      Affiliations

    • General Hospital of Treviso, Treviso, Italy
    • These authors contributed equally to this work.
  • ,
  • Poul H.B. Sorensen

      Affiliations

    • Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
    • These authors contributed equally to this work.
  • ,
  • Palma Dileo

      Affiliations

    • Sarcoma Unit, Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Laurence H. Baker

      Affiliations

    • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
    • These authors contributed equally to this work.
  • ,
  • Stefano Ferrari

      Affiliations

    • Istituto Ortopedico Rizzoli, Bologna, Italy
    • These authors contributed equally to this work.
  • ,
  • Kirsten Sundby Hall

      Affiliations

    • Division of Cancer Medicine and Radiotherapy, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Kirsten Sundby Hall, MD, Division of Cancer Medicine and Radiotherapy. The Norwegian Radium Hospital, Rikshospitalet University Hospital, NO-0310 Oslo, Norway

Small round cell sarcomas are the most aggressive of the tumors morphologically and clinically encountered in children and adults, and in some ways the most leukemia- or lymphoma-like of sarcomas. Small round cell sarcomas often are associated with chromosomal translocations, like hematologic malignancies, and are usually more sensitive to chemotherapy than other sarcoma subtypes. They have a high risk of mortality, but chemotherapy (in addition to surgery and often radiation therapy) provides a good cure rate, although treatment is often long and intensive. The biology of these tumors is very telling in terms of some of the mechanisms of cancer cell survival and proliferation. Although there is some overlap of the discussion below with the section on translocation associated sarcomas, we have highlighted some of the key issues with these sarcomas below, with some ideas that may bear fruit both in terms of the management of these, other sarcomas, and other cancers alike.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Stephen L. Lessnick is supported by the Terri Anna Perine Sarcoma Fund, the Liddy Shriver Sarcoma Initiative, American Cancer Society Research Scholar Grant No. MGO-111812, and a Huntsman Cancer Institute Director's Translational Research Initiative Grant. S.L.L. also acknowledges NIH support to Huntsman Cancer Institute via P30 CA042014. Poul H.B. Sorensen is supported by grants from the Canadian Institutes of Health Research (CIHR).

Disclosures Stephen L. Lessnick: Owns stock in Merck, Inc, the makers of vorinostat. Merck provided the vorinostat used in Dr Lessnick's studies.Laurence H. Baker: Hoffman-La Roche supports clinical trials and research by the Sarcoma Alliance for Research through Collaboration, on whose executive board Dr Baker is a member.

PII: S0093-7754(09)00106-7

doi:10.1053/j.seminoncol.2009.06.006

Seminars in Oncology
Volume 36, Issue 4 , Pages 338-346, August 2009